CPC A61K 45/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 31/045 (2013.01); A61K 31/047 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/245 (2013.01); A61K 31/445 (2013.01); A61K 31/7004 (2013.01); A61K 31/718 (2013.01); A61K 31/765 (2013.01); A61K 33/00 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/26 (2013.01); A61K 47/28 (2013.01)] | 19 Claims |
1. A slurry configured for injection into a target tissue comprising:
a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm, wherein the plurality of sterile ice particles are substantially uniform in shape; and
a biocompatible surfactant, wherein the biocompatible surfactant is glycerol;
the slurry having a mean temperature in the range of about 0° C. to about −15° C.;
wherein the target tissue is selected from the group consisting of adipose tissue and a myelinated nerve; and
wherein the slurry is configured to cause the target tissue to reach a temperature in the range of about −8° C. to about 0° C. such that crystallization occurs in the target tissue and the crystallization causes localized and selective damage to the target tissue.
|